Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Slides:

Advertisements

Similar presentations

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

Advertisements

Mild Cognitive Impairment

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁董冠廷詹鎮遠陳柏廷.

Cognitive Development Dementia. Stages: Preclinical First sign: memory loss for the familiar First sign: memory loss for the familiar Biological changes.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease Mirjana Babić.

Volume 3, Issue 4, Pages (November 2017)

Embracing Their Reality: Making Assisted Living Dementia-Friendly

Nat. Rev. Neurol. doi:10/1038/nrneurol

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Nat. Rev. Neurol. doi: /nrneurol

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample Marie Eckerström,

by Edward J. Goetzl, Adam Boxer, Janice B. Schwartz, Erin L

Imaging AD Progression Amyloid Imaging Agents.

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

Cognitive Disorders and Aging

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

New Therapies in Alzheimer's Disease

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Patterns of brain atrophy in Alzheimer disease

Nat. Rev. Neurol. doi: /nrneurol

Early Dementia Distinguishing AD From MCI

Figure 2 Proposed mechanism of Guillain–Barré

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The new concept of prodromal RBD

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

New FDA Guidance on Early Alzheimer’s Disease

Figure 3 Proportion of patients for whom NEDA

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Probing the Biology of Alzheimer's Disease in Mice

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Genetic pleiotropy in ALS

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 3 Stroke-related deaths and DALYs by country development status

Nat. Rev. Neurol. doi: /nrneurol

Todd E. Golde, Lon S. Schneider, Edward H. Koo Neuron

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Frequency of vertigo and dizziness syndromes

Figure 1 Tau PET images in patients with Alzheimer disease

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.

Nat. Rev. Neurol. doi: /nrneurol

Baseline Characteristics of the Subjects

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 A case of early-onset PSD

Massimo S. Fiandaca, Mark E. Mapstone, Amrita K. Cheema, Howard J

GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS Betty M. Tijms, Mara ten Kate, Sander C.J.

Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI

ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD) Figure 1 | Hypothetical staging model of sporadic Alzheimer disease (AD). Although many individuals with mild cognitive impairment (MCI) progress to dementia, some remain stable or revert to normal cognitive function. The proposed staging is based on the progression of the disease and comprises two bits of information: AD stage as identified at diagnosis, and the current stage. The main categories in this system include the preclinical (or presymptomatic) phase (1), the prodromal stage, also known as MCI (2), and the dementia syndrome (3). Hampel, H. & Lista, S. (2015) The rising global tide of cognitive impairment Nat. Rev. Neurol. doi:10.1038/nrneurol.2015.250